Impact of the COVID-19 Pandemic on Staging Oncologic PET/CT Imaging and Patient Outcome in a Public Healthcare Context: Overview and Follow Up of the First Two Years of the Pandemic DOI Open Access
Andrés Kohan,

Sumesh Menon,

Vanessa Murad

et al.

Cancers, Journal Year: 2023, Volume and Issue: 15(22), P. 5358 - 5358

Published: Nov. 10, 2023

To assess the impact of COVID-19 pandemic on diagnosis, staging and outcome a selected population throughout first two years pandemic, we evaluated oncology patients undergoing PET/CT at our institution. A retrospective lung cancer, melanoma, lymphoma head neck cancer staged using during 6 months 2019, 2020 2021 were included for analysis. The year in which PET was performed exposure variable, main outcomes stage time overall survival (OS). total 1572 PET/CTs purposes 2021. median age 66 (IQR 16), 915 (58%) males. most prevalent (643, 41%). univariate analysis OS by not significantly different. multivariate Cox regression non-COVID-19 different variables determined that (HR 1.76 CI95 1.23-2.53, p < 0.05), III 3.63 2.21-5.98, IV 11.06 7.04-17.36, 0.05) diagnosis 1.04 1.02-1.05, had increased risks death. We did find higher stages or reduced when assessing performed. Furthermore, modified staged, even controlled significant (age, type gender).

Language: Английский

The impact of the COVID-19 pandemic on time to treatment in head and neck cancer management: a systematic review DOI Creative Commons

Malte Grumstrup Simonsen,

Amanda‐Louise Fenger Carlander, Kathrine Kronberg Jakobsen

et al.

Acta Oncologica, Journal Year: 2025, Volume and Issue: 64, P. 156 - 166

Published: Jan. 28, 2025

Background and purpose: Coronavirus disease 2019 (COVID-19) caused a need for reorganization in the healthcare systems. First, we aimed to determine impact of COVID-19 pandemic on time treatment head neck cancer (HNC) patients. Second, tumor stage changes regimens used. Material methods: A systematic search PubMed Embase was conducted according Preferred Reporting Items Systematic Reviews Meta-Analyses guidelines. Inclusion criteria were: (1) Studies including patients with squamous cell carcinomas; (2) containing comparison treatment; (3) well-defined interval restrictions health care due without restrictions. Results: total 19 studies were included comprising 24,898 treated HNC cancer. Six (10.1% patients) reported an increase waiting within at least one interval, while seven decrease (83.2% patients), six found no significant effect. No modalities observed. Seven 15 (12.7% observed either overall stage, size, or node metastasis classification during pandemic. Among these, two increased times as well. Interpretation: The COIVD-19 heterogenous subject considerable intercountry interregional variations. tendency toward higher T-classification In conclusion, otorhinolaryngology departments demonstrated resilience, led only slight alterations treatment.

Language: Английский

Citations

1
Impact of the Sars-Cov-2 outbreak on the initial clinical presentation of new solid cancer diagnoses: a systematic review and meta-analysis DOI Creative Commons

Simon Marty,

Guillaume Lamé, Etienne Guével

et al.

BMC Cancer, Journal Year: 2024, Volume and Issue: 24(1)

Published: Jan. 29, 2024

Abstract Background The COVID-19 pandemic might have delayed cancer diagnosis and management. aim of this systematic review was to compare the initial tumor stage new diagnoses before after pandemic. Methods We systematically reviewed articles that compared solid waves. conducted a random-effects meta-analysis rate metastatic tumors distribution stages at diagnosis. Subgroup analyses were performed by primary site country. Results From 2,013 studies published between January 2020 April 2022, we included 58 with 109,996 patients. higher outbreak than (pooled OR: 1.29 (95% CI, 1.06-1.57), I 2 : 89% 86-91)). For specific cancers, common ORs reached statistical significance for breast (OR: 1.51 CI 1.07-2.12)) gynecologic 1.04-2.18)) but not other types. According countries, OR CI) only Italy: 1.55 (1.01-2.39) Spain:1.14 (1.02-1.29). Rates comparable I-II versus III-IV in which information available, III did include Conclusions Despite inter-study heterogeneity, our showed burden social distancing policies explain those results, as patients may seeking care.

Language: Английский

Citations

6
Impact of the COVID‐19 pandemic on stage and incidence of head and neck cancer: A rapid review and meta‐analysis DOI
Kelten Clements, Alekh Thapa, Anna Cowell

et al.

Clinical Otolaryngology, Journal Year: 2024, Volume and Issue: 49(4), P. 363 - 375

Published: March 21, 2024

Abstract Objectives This rapid review aims to evaluate the impact of COVID‐19 pandemic on incidence head and neck cancer (HNC) stage distribution at diagnosis. Design Rapid meta‐analysis. Participants Comparative data for new HNC patients between a pre‐pandemic cohort (before March 2020) (after 2020 during lockdown period). Main Outcomes Measured Data tumour stage, incidence, referral pathway (number patient referrals), or workload levels treatments). were summarised as odds ratios (OR) with 95% confidence intervals (CI), related changes in numbers diagnoses, referrals, narrative synthesis. Results A total 31 reports included this review. Individually 16 out 23 studies did not show significant relative period. However, meta‐analysis revealed that diagnosed 16% more likely have nodal involvement (OR = 1.16; CI 1.00–1.35), 17% late overall 1.17; 1.01–1.36), 32% present advanced extent (T3 T4 stage) 1.32; 1.08–1.62). was extremely limited currently sufficient assess trends burden disease. Conclusions indicates pandemic, there upstaging diagnosis, suggesting provision care significantly affected.

Language: Английский

Citations

4
Stage shift and relative survival for head and neck cancer during the 2020 COVID-19 pandemic: a population-based study of temporal trends DOI Creative Commons
Hanna M. Peacock, Cindy De Gendt, Geert Silversmit

et al.

Frontiers in Oncology, Journal Year: 2023, Volume and Issue: 13

Published: Sept. 20, 2023

During the first wave of COVID-19 pandemic in 2020, non-essential health services were suspended Belgium, and public was ordered to socially isolate. Underdiagnosis cancer during this period reported worldwide. Certain risk factors for head neck (HNC) overlap with those incidence mortality, making underdiagnosis subsequent stage shift potentially rapidly progressing a major concern. We aimed analyze incidence, clinical at presentation, survival patients diagnosed HNC 2020 considering recent temporal trends.Using population-based data from Belgian Cancer Registry (BCR), we extrapolated 2017-2019 trends stage, 1-year relative (1yRS) create an expected value compared observed value.There 9.5% fewer HNCs predicted incidence. larger males (-11.8%), aged 50-64 (-11.2%) 65-79 (-11.1%), oral cavity (-17.6%). Shifts more advanced stages larynx oropharynx tumors (male) 80+. A 2.4 percentage point decline 1yRS observed, increasing (2017-2019).The led HNC, resulting shifts presentation certain subgroups. can be not yet end 2020. suffered higher than mortality.

Language: Английский

Citations

9
Impact of the Sars-COVID-19 Pandemic on the “Early Diagnosis” of Laryngeal Tumors: Data From Monocentric Tertiary Care Hospital of South Italy DOI
Cosimo Galletti,

Laura De Marco,

Francesco Ciodaro

et al.

Journal of Voice, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Language: Английский

Citations

2
The Effects of the COVID-19 Pandemic on Cancer Staging in Patients Diagnosed With Head and Neck Cancer DOI Open Access

Delanie P. Mack,

Horace J. Spencer, Kaidi Wang

et al.

Cureus, Journal Year: 2023, Volume and Issue: unknown

Published: Jan. 25, 2023

Purpose The healthcare system across the world was forced to implement new policies, guidelines, and procedures due coronavirus disease 2019 (COVID-19) pandemic, which led many patients make an impossible choice about their health. For various reasons, chose remain at home delay any interaction medical facilities protect themselves or others from virus. Patients managing chronic diseases faced unprecedented challenges during this period, long-term effects on these patient populations unclear. Oncology patients, specifically those diagnosed with head neck cancers, require prompt diagnosis initiation of treatment for better outcomes. While overall impact how pandemic has affected oncology is unknown, retrospective study examined staging tumors our institution been impacted since beginning pandemic. Methods Available data (from August 1, 2019, through June 28, 2021) were collected records compared determine statistical significance. categorized into a Pre-pandemic group, Pandemic Vaccine-approved characteristics analyzed look patterns. pre-pandemic period defined as March 16, 2020, 17, December 31, vaccine-approved January 2021, 2021. Results Fisher's exact tests used compare tumor, node, metastasis (TNM) distributions between three groups. In out 67 33 (55.0%) T stage 0-2 27 (45.0%) 3-4. groups, 139 50 (39.1%) 78 (60.9%) 3-4; differences statistically significant (P-value = 0.0426). group had 25 (41.7%) 35 (58.3%) groups 36 (28.1%) 92 (71.9%) results trended 0.0688). Conclusions Our findings suggest that there have higher number cancer 3 4 start COVID-19 are ongoing will need further evaluation patients. Increased morbidity mortality rates may be potential result in years come.

Language: Английский

Citations

6
Impact of the COVID-19 Pandemic on the Surgical Management of Head and Neck Non-Melanoma Skin Cancers in a Maxillofacial Center of Cluj-Napoca DOI Open Access
Rareș Călin Roman, Cosmin Ioan Faur,

Edina Gordan

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(13), P. 3934 - 3934

Published: July 4, 2024

: The COVID-19 era has been a bleak period for both cancer and non-cancer patients, with delayed non-emergency treatments, such as non-melanoma skin (NMSC). This study aimed to evaluate how the treatment of NMSC patients was influenced by management pandemic in an Eastern European Maxillofacial Surgery center.

Language: Английский

Citations

1
The impact of the COVID-19 pandemic on diagnosis and treatment of patients with soft tissue and bone sarcomas or aggressive benign musculoskeletal diseases: A single-center retrospective study (SarCorD study) DOI Creative Commons
Concetta Elisa Onesti, Sabrina Vari, Francesca Nardozza

et al.

Frontiers in Oncology, Journal Year: 2022, Volume and Issue: 12

Published: Sept. 20, 2022

The COVID-19 pandemic led to a rapid reorganization of healthcare activities, leading reduced access clinics, interruption screenings, and treatment schedule modifications in several cancer types. Few data are available on sarcomas. We analyzed COVID-19-related diagnostic delay sarcoma referral center Italy.We retrospectively enrolled this study patients with histological diagnosis soft tissue or bone aggressive benign musculoskeletal diseases obtained during the first year (Covid group) before (Control followed at Regina Elena National Cancer Institute Rome. primary endpoint was time from symptom diagnosis.We evaluated 372 patients, 185 whom were eligible for analysis (92 Control group 93 Covid group). affected by most cases (63.0% 66.7% groups, respectively). observed median definitive 103.00 days (95% CI 92.77-113.23) vs. 90.00 69.49-110.51) (p = 0.024), but not beginning (151 days, 95% 132.9-169.1 144 120.3-167.7, respectively, p 0.208). No differences stage (12% 16.5% metastatic disease 0.380). Progression-free survival 0.897) overall 0.725) comparable subgroup sarcoma.A starting has been pandemic. Nevertheless, no difference terms observed.

Language: Английский

Citations

7
Impact of the COVID-19 pandemic on the diagnosis and treatment of patients with head and neck cancer in Brandenburg and Berlin DOI

J. Carré,

Beatrice Herzog,

Daniela Reil

et al.

HNO, Journal Year: 2023, Volume and Issue: 72(2), P. 90 - 101

Published: Dec. 20, 2023

Citations

3
Einfluss der Corona-Pandemie auf Diagnostik und Therapie von Kopf-Hals-Tumoren DOI Creative Commons

Benjamin Prokein,

Michael Dau, Bernhard Frerich

et al.

HNO, Journal Year: 2024, Volume and Issue: 72(12), P. 893 - 899

Published: Nov. 6, 2024

Zusammenfassung Hintergrund Nach Auftreten der ersten COVID-19-Fälle hatte sich das Virus innerhalb weniger Monate weltweit verbreitet. Hierbei zeigte ein Rückgang an ärztlichen Konsultationen. Die vorliegende Studie untersucht, ob dies Auswirkungen auf die Diagnose und Therapie von Kopf-Hals-Tumorerkrankungen – bezogen den Zeitraum 2018 bis 2022. Material Methode Kopf-Hals-Tumordaten des Klinischen Krebsregisters (KKR) Mecklenburg-Vorpommern aus dem 2020–2022 wurden beiden Vorjahren (2018, 2019) gegenübergestellt. Erfasst demografische Daten, Fallzahlen, Daten zu Diagnose, ICD TNM-Klassifikation. vom Robert Koch-Institut (RKI) abgefragt. mittels Mann-Whitney-U-Test Korrelation nach Pearson analysiert. Ergebnisse Insgesamt konnten 2332 Patientenfälle in eingeschlossen werden. Im Rahmen Lockdowns weder signifikanter Tumormeldungen KKR noch eine signifikante zwischen COVID-19-Fallzahlen Tumordiagnosen. Signifikante Unterschiede zeigten T‑Kategorie im Jahr 2022 Prä-COVID-19-Jahren 2019. Außerdem wurde Verschiebung relativen Häufigkeiten einzelnen ICD-10-Codes beobachtet. Schlussfolgerung COVID-19-Pandemie keine signifikanten beim Vergleich Jahre Entgegen Erwartungen eines Rückgangs Fallzahlen Pandemie durch Lockdown mit Erhöhung Tumorstadien konnte sogar Reduktion gefunden werden sowie einzelner über Pandemie.

Citations

0